News
FBRX
0.5799
-3.35%
-0.0201
Weekly Report: what happened at FBRX last week (0520-0524)?
Weekly Report · 1d ago
Weekly Report: what happened at FBRX last week (0513-0517)?
Weekly Report · 05/20 11:03
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
Forte Biosciences, Inc. Is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The company announced the issuance of equity inducement awards to new non-executive employees. The Company is advancing its product candidate, FB102.
Barchart · 05/17 15:05
Analysts Offer Insights on Healthcare Companies: Sutro Biopharma (STRO), Edgewise Therapeutics (EWTX) and Forte Biosciences (FBRX)
TipRanks · 05/14 12:02
FBRX Stock Earnings: Forte Biosciences Reported Results for Q1 2024
Forte Biosciences reported earnings per share of -16 cents for the first quarter of 2024. The company did not report any revenue for the quarter. InvestorPlace Earnings is a project that automates coverage of quarterly earnings reports. Forte B biosciences just reported results for first quarter 2024.
Investorplace · 05/14 01:54
Forte Biosciences, Inc. Quarterly Report: Condensed Consolidated Financial Statements and Management's Discussion and Analysis
Press release · 05/13 22:56
Forte Biosciences Inc: Quarterly report
Press release · 05/13 22:44
Forte Biosciences Inc reports results for the quarter ended in January - Earnings Summary
Forte Biosciences Inc reports results for the quarter ended in January. The company reported a quarterly adjusted loss of 16 cents per share. The mean expectation of two analysts was for a loss of -16 cents. The average analyst rating on the shares is "strong buy"
Reuters · 05/13 21:35
Forte Biosciences GAAP EPS of -$0.16
Forte Biosciences GAAP EPS of -$ for Q1 of 2024. Research and development expenses were $ million for the three months ended March 31, 2024, compared to $ $ for the same period in 2023. FBRX: Q1 GAAP earnings per share was -$.
Seeking Alpha · 05/13 21:16
Forte Biosciences Q1 2024 GAAP EPS $(0.32) Misses $(0.17) Estimate
Benzinga · 05/13 20:22
Press Release: Forte Biosciences, Inc. Announces -2-
Dow Jones · 05/13 20:06
Press Release: Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update
Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update. The company is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. Forte continues to make excellent progress with its FB102 program.
Dow Jones · 05/13 20:06
FORTE BIOSCIENCES, INC. ANNOUNCES FIRST QUARTER 2024 RESULTS AND PROVIDES BUSINESS UPDATE
Reuters · 05/13 20:05
FORTE BIOSCIENCES Q1 INCOME FROM OPERATIONS USD -7.804 MILLION
Reuters · 05/13 20:05
*Forte Biosciences 1Q Loss/Shr 16c >FBRX
Dow Jones · 05/13 20:05
*Forte Biosciences 1Q Loss $7.42M >FBRX
Dow Jones · 05/13 20:05
Weekly Report: what happened at FBRX last week (0506-0510)?
Weekly Report · 05/13 11:12
Forte Biosciences Inc <FBRX.OQ> expected to post a loss of 16 cents a share - Earnings Preview
Forte Biosciences Inc expected to post a loss of 16 cents a share. The average analyst rating on the shares is "strong buy" for the period ending March 31 2024. The company is expected to report results on May 13. The median 12-month price target for the company is $2.88.
Reuters · 05/10 11:25
Weekly Report: what happened at FBRX last week (0429-0503)?
Weekly Report · 05/06 11:19
Weekly Report: what happened at FBRX last week (0422-0426)?
Weekly Report · 04/29 11:26
More
Webull provides a variety of real-time FBRX stock news. You can receive the latest news about Forte Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About FBRX
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company’s FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Company’s subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.